Akari Therapeutics (AKTX) Capital Expenditures (2016)
Akari Therapeutics (AKTX) reported Capital Expenditures of $42083.0 for Q1 2016.
Akari Therapeutics (AKTX) Capital Expenditures (2016) Analysis & Trends
Akari Therapeutics (AKTX) has 1 years of Capital Expenditures data on file, last reported at $42083.0 in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 786,000.00 |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 21.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 42,083.00 |
| Mar 31, 2016 | 42,083.00 |